Literature DB >> 26969870

Idiopathic histaminergic angioedema without wheals: a case series of 31 patients.

C Faisant1,2, I Boccon-Gibod1,3, C Mansard1,2, C Dumestre Perard4, P Pralong5, C Chatain5, A Deroux1,2,3, L Bouillet1,2,3,6.   

Abstract

Idiopathic histaminergic acquired angioedema (IH-AAE) is a common cause of recurrent angioedema without wheals. It is a mast cell-mediated disease thought to belong to the same clinical entity as chronic urticaria (CU). The objective of this study was to describe the clinical and epidemiological characteristics of IH-AAE patients. From 2014 to 2015, 534 patients were seen at our national reference centre for angioedema and/or urticaria. Among them, we identified 31 patients with idiopathic histaminergic acquired angioedema without wheals (IH-AAE). Thirty-one patients (15 men and 16 women) with a mean age of 50 years met the criteria for IH-AAE. The average delay in diagnosis was 6·3 years. A history of allergy was found in 12 patients (38·7%), nine suffering from allergic rhinitis. The mean duration of attacks was 28·1 h. The AE attack was located in the upper respiratory tract in 54·8% of cases (17 patients). A lingual location was found in 29% of patients. Men were more likely than women to have an upper airway involvement. No intubations or admissions to intensive care units were reported. The dosage of anti-histamines to control the symptoms was onefold the recommended dose in 51·6% of patients (16 patients), twofold in 32% (10 patients) and three-fourfold in 16·1% (five patients). IH-AAE is characterized by an important delay in diagnosis, a frequent involvement of the upper airway and a benign course during attacks. As in CU, a trial of up to fourfold dose of H1-anti-histamines may be necessary to control symptoms.
© 2016 British Society for Immunology.

Entities:  

Keywords:  Allergy; Inflammation; Mast Cells; Skin

Mesh:

Substances:

Year:  2016        PMID: 26969870      PMCID: PMC4908297          DOI: 10.1111/cei.12789

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  17 in total

Review 1.  Chronic urticaria.

Authors:  M Greaves
Journal:  J Allergy Clin Immunol       Date:  2000-04       Impact factor: 10.793

Review 2.  Angioedema.

Authors:  Allen P Kaplan; Malcolm W Greaves
Journal:  J Am Acad Dermatol       Date:  2005-09       Impact factor: 11.527

3.  The diagnosis and management of anaphylaxis: an updated practice parameter.

Authors: 
Journal:  J Allergy Clin Immunol       Date:  2005-03       Impact factor: 10.793

4.  Corticosteroids should not be used in urticaria because of the potential risk of steroid dependence and development of severe anti-H1- resistant urticaria.

Authors:  Frédéric Augey; Audrey Nosbaum; Frédéric Berard; Jean-François Nicolas
Journal:  Eur J Dermatol       Date:  2011 May-Jun       Impact factor: 3.328

5.  Suppression of histamine-induced skin reactions by loratadine and cetirizine diHCl.

Authors:  K Kontou-Fili; G Paleologos; M Herakleous
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 6.  Recurrent angioedema: diagnosis strategy and biological aspects.

Authors:  Laurence Bouillet; Isabelle Boccon-Gibod; Frédéric Berard; Jean-François Nicolas
Journal:  Eur J Dermatol       Date:  2014 May-Jun       Impact factor: 3.328

7.  Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group.

Authors:  M Cicardi; W Aberer; A Banerji; M Bas; J A Bernstein; K Bork; T Caballero; H Farkas; A Grumach; A P Kaplan; M A Riedl; M Triggiani; A Zanichelli; B Zuraw
Journal:  Allergy       Date:  2014-03-27       Impact factor: 13.146

Review 8.  Gender-related differences in chronic urticaria.

Authors:  Nicoletta Cassano; Delia Colombo; Gilberto Bellia; Emanuela Zagni; Gino A Vena
Journal:  G Ital Dermatol Venereol       Date:  2015-06-19       Impact factor: 2.011

9.  Double-blind crossover study of high-dose cetirizine in cholinergic urticaria.

Authors:  T Zuberbier; C Münzberger; U Haustein; E Trippas; B Burtin; S D Mariz; B M Henz
Journal:  Dermatology       Date:  1996       Impact factor: 5.366

10.  Usefulness of a short course of oral prednisone in antihistamine-resistant chronic urticaria: a retrospective analysis.

Authors:  R Asero; A Tedeschi
Journal:  J Investig Allergol Clin Immunol       Date:  2010       Impact factor: 4.333

View more
  6 in total

Review 1.  Idiopathic Non-histaminergic Angioedema: Successful Treatment with Omalizumab in Five Patients.

Authors:  Charles Faisant; Aurélie Du Thanh; Catherine Mansard; Alban Deroux; Isabelle Boccon-Gibod; Laurence Bouillet
Journal:  J Clin Immunol       Date:  2016-11-08       Impact factor: 8.317

2.  Angioedema suppressed by a combination of anti-histamine and leukotriene modifier.

Authors:  Brendan N Wong; Peter Vadas
Journal:  Allergy Asthma Clin Immunol       Date:  2017-06-13       Impact factor: 3.406

3.  Profile of serious angioedema requiring an urgent advice from a national reference call center.

Authors:  Nicolas Simon; Alexis Bocquet; Isabelle Boccon-Gibod; Laurence Bouillet
Journal:  Medicine (Baltimore)       Date:  2022-08-05       Impact factor: 1.817

4.  Idiopathic non-histaminergic acquired angioedema: a case series and discussion of published clinical trials.

Authors:  Martin Christian Bucher; Tatjana Petkovic; Arthur Helbling; Urs Christian Steiner
Journal:  Clin Transl Allergy       Date:  2017-08-31       Impact factor: 5.871

Review 5.  Efficacy of Treatment of Non-hereditary Angioedema.

Authors:  Mignon van den Elzen; M F C L Go; A C Knulst; M A Blankestijn; H van Os-Medendorp; H G Otten
Journal:  Clin Rev Allergy Immunol       Date:  2018-06       Impact factor: 8.667

Review 6.  Differences and Similarities in the Mechanisms and Clinical Expression of Bradykinin-Mediated vs. Mast Cell-Mediated Angioedema.

Authors:  Marcus Maurer; Markus Magerl
Journal:  Clin Rev Allergy Immunol       Date:  2021-02-03       Impact factor: 8.667

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.